Case report

Meningoencephalitis from SARS-CoV-2 infection

Fatima Hafizi,a,⁎ Saleema Kherani,a Madeeha Shamsb

aMedStar Harbor Hospital, 3001 S Hanover St, Baltimore, MD 21225, United States
b2850 North Ridge Road, Suite 102, Ellicott City, MD 21043, United States

A R T I C L E   I N F O
Article history:
Received 2 June 2020
Received in revised form 15 July 2020
Accepted 16 July 2020

Keywords:
COVID-19
SARS-CoV-2
Coronavirus
Meningoencephalitis
Nervous system
CSF

A B S T R A C T
The current global pandemic of COVID-19 disease is caused by a novel coronavirus SARS-CoV-2. This typically causes severe respiratory illness, however, as cases have multiplied across the globe, protean manifestations involving multiple organ systems have been described. We report a case of a 35-year-old woman with meningoencephalitis associated with COVID-19 disease who presented with altered mental status and rhythmic limb movements. Although rare, meningoencephalitis should be considered as a possible manifestation of COVID-19 disease.

© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
The novel coronavirus, named SARS-CoV-2, is known to have emerged in Wuhan, China in late 2019. Its high infectivity has allowed it to spread across the globe, leading to a worldwide pandemic [1,2]. While research continues to elucidate its mechanism of infection, clinical manifestations and key targets for drug therapy, a wide variety of organs have been found to be involved with SARS-CoV-2 infection. Recent reports indicate that the CNS is not spared.

Headache, dysesthesia and hyposmia have been reported as the common nonspecific neurologic symptoms of COVID-19 infection [3–5], however, more serious neurologic manifestations including encephalopathy [6,7], Guillain Barre syndrome [8] and stroke [9,10] are now being reported as the number of patients with COVID-19 multiplies across the globe. We report a case of meningoencephalitis associated with SARS-CoV-2 who presented with altered mental status.

Case report
A 35-year-old woman with newly diagnosed diabetes presented to the emergency department (ED) with altered mental status. She had been complaining of a persistent generalized headache for one week that was partially relieved with acetaminophen and ibuprofen. Four days prior, she had developed a non-productive cough and sore throat without any documented fever. On the day of presentation, her husband noted that she was lethargic and confused. He later found her unresponsive and having random rhythmic movements of bilateral upper and lower extremities, then called emergency medical services. She did not have any tongue biting, fecal or urinary incontinence. It was reported that over the past two weeks the patient had been taking food to a COVID-19 positive family member but ensuring no close contact. Otherwise, she had no history of substance use, smoking or recent travel.

Upon arrival to the ED, the patient had a Glasgow Coma Scale (GCS) of 9 (E4 V1 M4). She was afebrile with temperature 36.6 C, heart rate 93, and blood pressure 133/70. She had no nuchal rigidity on physical exam, and Brudzinski and Kernig’s signs were negative. Due to agitation and vomiting, endotracheal intubation was performed for airway protection. Laboratory tests showed white blood cell count of 6900/μL and lactate of 1.1 mmol/L. A head CT without contrast showed no abnormalities and a urinalysis was negative. A chest x-ray showed bilateral patchy infiltrates and a nasopharyngeal SARS-CoV-2 PCR resulted positive. Pharyngeal swab for rapid Streptococcus test was also positive for Streptococcus pyogenes. Blood cultures were drawn. Patient was empirically started on vancomycin, ceftriaxone and acyclovir. An initial lumbar puncture attempt was unsuccessful, and she was admitted to the intensive care unit.

On day 2, fluoroscopy-guided lumbar puncture was performed and obtained 12 mL of initially clear then bloody fluid. Cerebrospinal fluid (CSF) analysis showed glucose of 109 mg/dL (normal 40–70 mg/dL), protein of 250 mg/dL (normal 12–60 mg/
dl), RBC of 231/mm³ and WBC of 42/mm³ with 62% lymphocytes and 4% monocytes consistent with aseptic meningitis. Opening pressure could not be measured due to slow flow of CSF. Infectious workup of the CSF resulted negative for varicella zoster virus PCR, herpes simplex virus 1 and 2 PCR, enterovirus/echovirus PCR, syphilis testing with VDRL and cryptococcal antigen. SARS-CoV-2 testing could not be performed on the CSF sample because our facility did not have the requisite validation to perform such a test. MRI brain could not be performed due to hospital policy to minimize unnecessary exposures to COVID-19 disease.

Serum inflammatory markers on admission showed elevated C-reactive protein (23.0 mg/L), erythrocyte sedimentation rate (34 mm/hr), and D-dimer (0.51 µg/mL) but normal ferritin (125.3 ng/mL), lactate dehydrogenase (267 U/L) and interleukin-6 levels (<5 mg/L). Blood and CSF cultures finalized negative on day 5. Vancomycin was discontinued after two days. Ceftriaxone was continued for streptococcal pharyngitis and acyclovir for possible herpes simplex encephalitis. By day four, her mental status markedly improved and she was extubated. She was discharged home on day nine to complete ten days of anti-infective therapy (PO penicillin V and PO valacyclovir).

Discussion

The neuroinvasive nature of human coronavirus has been previously reported during the 2002–2003 SARS-CoV pandemic when viral nucleic acids were found in the human brain upon autopsies [11]. It was postulated by scientists in China that SARS-CoV-2, a novel coronavirus from the SARS-CoV family, could also infect the brain when they observed neurologic signs among patients with COVID-19 related respiratory illness [12]. A recent report from Japan described the first case presenting with SARS-CoV-2 meningoencephalitis which was associated with increased signal intensity in the hippocampus, similar to SARS-CoV encephalitis [6]. The similitude is believed to be due to similarity in the angiotensin converting enzyme 2 receptor binding domain for both viruses [12]. However, to date, there is insufficient clinical and pathophysiologic data to postulate the exact mechanism by which SARS-CoV-2 infects the nervous system.

Brain imaging in our patient was performed using computed tomography. Although a subsequent MRI may have been helpful with diagnosis, it was not performed to prevent spread of SARS-CoV2 to others. Likewise, a definitive diagnosis of viral encephalitis depends on the ability to detect or culture the virus from CSF or brain tissue. This can be difficult as SARS-CoV-2 is transiently disseminated and its titer in CSF can be low [13]. Our patient had CSF findings of meningoencephalitis but all viral PCR studies resulted negative.

HSV encephalitis detected with PCR has a very high specificity, but it has been found that the sensitivity is lower early in the disease process [14]. Given our patient’s rapid improvement, the risks of repeating lumbar puncture to check HSV PCR outweighed the benefits. Therefore, she was empirically given a complete course of acyclovir. However, her rapid dervescence is not typical of HSV CNS infection even with the timely initiation of antiviral treatment. Therefore, we speculate that our patient had a CNS infection associated with SARS-CoV-2.

Unfortunately, SARS-CoV-2 testing could not be performed due to lack of validation for the test at our facility. Testing through viral culture from CSF or brain tissue would require a biosafety level 3 lab and would be very resource intensive. Detecting SARS-CoV-2 RNA would be a much more feasible approach for the majority of hospitals. This case clearly demonstrates the need to make COVID-19 testing in CSF widely available in acute care settings.

Conclusion

Although rare, meningoencephalitis should be considered as a possible manifestation of COVID-19 disease. A suspicion for SARS-CoV-2 meningitis or encephalitis should be high among patients presenting with neurological symptoms during this era of pandemic. SARS-CoV-2 testing should be included as part of the workup in addition to other infectious causes.

Funding

This research did not receive any grants from funding agencies in the public, commercial, or non-profit sectors.

Declaration of Competing Interest

Authors declare no conflicts of interest.

References

[1] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in wuhan, china. JAMA 2020;323(11):1061–9. doi:http://dx.doi.org/10.1001/jama.2020.1585.
[2] Wang Y, Wang Y, Chen Y, et al. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol 2020;92(6):568–76. doi:http://dx.doi.org/10.1002/jmv.25746.
[3] Vayougios GD. Potentially irreversible olfactory and gustatory impairments in COVID-19: indolent vs. fulminant SARS-CoV-2 neuroinfection. Brain Behav Immun 2020; doi:http://dx.doi.org/10.1016/j.bbi.2020.04.071.
[4] Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in china. N Engl J Med 2020;382(18):1708–20. doi:http://dx.doi.org/10.1056/NEJMo2002032.
[5] Lechien JR, Chiesa-Estomba CM, de Santi DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020, doi:http://dx.doi.org/10.1007/s00405-020-05956-1.
[6] Moriguchi T, Harit N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-CoV-2–infected CSF. Int J Infect Dis 2020;94:55–8. doi:http://dx.doi.org/10.1016/j.ijid.2020.03.062.
[7] Sohal S, Mossammam M. COVID-19 presenting with seizures. IDCases 2020e00782, doi:http://dx.doi.org/10.1016/j.idcr.2020.e00782.
[8] Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-barré syndrome associated with SARS-CoV-2 infection: Causality or coincidence? Lancet Neurol 2020;19 (5):383–4. doi:http://dx.doi.org/10.1016/S1474-4422(20)30199-9.
[9] Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, china. JAMA Neurol 2020, doi:http://dx.doi.org/10.1001/jamaneurol.2020.1127.
[10] Al Saiegh F, Ghosh R, Leibold A, et al. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID–19 and stroke. J. Neurol. Neurosurg. Psychiatry 2020.
[11] Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005;202(3):415–24, doi:http://dx.doi.org/10.1084/jem.20050828.
[12] Li Y, Bai W, Hashikawa T. The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID–19 patients. J Med Virol 2020;92 (6):552–5, doi:http://dx.doi.org/10.1002/jmv.25728.
[13] Ye M, Ren Y, Lu T. Encephalitis as a clinical manifestation of COVID–19. Brain Behav Immun 2020, doi:http://dx.doi.org/10.1016/j.bbi.2020.04.017.
[14] Denes E, Labach G, Duros H, et al. Intrathelial synthesis of specific antibodies as a marker of Herpes Simplex encephalitis in patients with negative PCR. Swiss Med Wkly 2010, doi:http://dx.doi.org/10.4414/smw.2010.13107.